AstraZeneca Plans Production Rationalization and Job Cuts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

AstraZeneca Plans Production Rationalization and Job Cuts


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

London (Feb. 1)—AstraZeneca PLC (www.astrazeneca.com) unveiled a plan to improve asset utilization within its global supply chain that involves rationalizing production assets and cutting staff. The company made the announcement as part of its fourth quarter and full-year 2006 financial results. 

Over the next three years, AstraZeneca plans to rationalize production assets, anticipating accounting charges of roughly $500 million, and reduce its workforce by 3000, subject to consultations with work councils, trade unions, and other employee representatives and in accordance with local labor laws. The company did not disclose which particular facilities would be affected.

“Going forward, management remains committed to maintaining a competitive financial performance during a period when the company, as well as the industry, faces the challenges imposed by patent expirations and pricing pressures from the government and private-sector players,” said the company in a prepared statement in explaining the rationale for the cost reductions.

For 2006, AstraZeneca reported an 11% sales gain to $26.5 billion and a 28% gain in profit to $6.04 billion.

AstraZeneca acquires biotech company

In another move, AstraZeneca agreed to acquire Arrow Therapeutics Ltd. (London, www.arrowt.co.uk), a privately held biotechnology company, for $150 million. Arrow Therapeutics is focused on the discovery and development of antiviral therapies. It has 57 employees at its facilities in London.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here